Evaluation of the role of RANK and OPG genes in Paget's disease of bone

被引:92
作者
Wuyts, W
Van Wesenbeeck, L
Morales-Piga, A
Ralston, S
Hocking, L
Vanhoenacker, F
Westhovens, R
Verbruggen, L
Anderson, D
Hughes, A
Van Hul, W
机构
[1] Univ Instelling Antwerp, Dept Med Genet, B-2610 Wilrijk, Belgium
[2] Hosp Ramon y Cajal, Dept Rheumatol, E-28034 Madrid, Spain
[3] Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland
[4] Univ Antwerp Hosp, Dept Radiol, Antwerp, Belgium
[5] Katholieke Univ Leuven Hosp, Dept Rheumatol, Louvain, Belgium
[6] Free Univ Brussels, Hosp Brussels, Dept Rheumatol, Brussels, Belgium
[7] Immunex Corp, Seattle, WA USA
[8] Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland
关键词
receptor activator of nuclear factor kappa B (RANK); osteoprotegerin (OPG); Paget's disease of bone; mutation analysis; polymorphism; bone;
D O I
10.1016/S8756-3282(00)00411-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paget's disease of bone (PDB) is one of the most common bone disorders in the western world. PDB is characterized by focal areas of increased osteoclastic bone resorption and bone formation, which leads to the formation of poorly structured bone. These abnormalities of bone turnover and structure predispose affected individuals to various complications including bone pain, deformity, pathological fracture, and an increased risk of osteosarcoma, One of the main mechanisms of osteoclast formation and activation involves the receptor activator of nuclear factor -kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway, where binding of RANKL to RANK results in the differentiation of osteoclast precursors. OPG, on the other hand, acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL, Recently, mutations in the RANK gene have been shown to cause familial expansile osteolysis, a rare bone disorder showing great similarity to PDB, We performed mutation analysis in the RANK and OPG genes in 28 PDB patients to investigate whether mutations in these genes could be responsible for PDB, Our data suggest that RANK is not directly involved in PDB in our set of patients, as no mutations in the RANK coding region could be identified and allele frequencies of RANK polymorphisms did not differ in PDB patients as compared with the random population. Also, in the OPG gene, we could not detect PDB-causing mutations. However, of the several polymorphisms identified, one (400 + 4 C/T in intron 2), showed a statistically significant increased frequency for the C allele in PDB patients, suggesting that individuals harboring this allele may be more susceptible for developing PDB, (C) 2001 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:104 / 107
页数:4
相关论文
共 17 条
[1]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]   THE EPIDEMIOLOGY OF PAGETS-DISEASE OF BONE [J].
BARKER, DJP .
BRITISH MEDICAL BULLETIN, 1984, 40 (04) :396-400
[3]   Genetic linkage of Paget disease of the bone to chromosome 18q [J].
Cody, JD ;
Singer, FR ;
Roodman, GD ;
Otterund, B ;
Lewis, TB ;
Leppert, M ;
Leach, RJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (05) :1117-1122
[4]  
FOTINO M, 1977, TRANSPLANT P, V9, P1867
[5]   Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity [J].
Haslam, SI ;
Van Hul, W ;
Morales-Piga, A ;
Balemans, W ;
San-Millan, JL ;
Nakatsuka, K ;
Willems, P ;
Haites, NE ;
Ralston, SH .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (06) :911-917
[6]   Familial Paget's disease of bone: Patterns of inheritance and frequency of linkage to chromosome 18q [J].
Hocking, L ;
Slee, F ;
Haslam, SI ;
Cundy, T ;
Nicholson, G ;
van Hul, W ;
Ralston, SH .
BONE, 2000, 26 (06) :577-580
[7]   Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis [J].
Hughes, AE ;
Ralston, SH ;
Marken, J ;
Bell, C ;
MacPherson, H ;
Wallace, RGH ;
van Hul, W ;
Whyte, MP ;
Nakatsuka, K ;
Hovy, L ;
Anderson, DM .
NATURE GENETICS, 2000, 24 (01) :45-48
[8]   Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].
Lacey, DL ;
Timms, E ;
Tan, HL ;
Kelley, MJ ;
Dunstan, CR ;
Burgess, T ;
Elliott, R ;
Colombero, A ;
Elliott, G ;
Scully, S ;
Hsu, H ;
Sullivan, J ;
Hawkins, N ;
Davy, E ;
Capparelli, C ;
Eli, A ;
Qian, YX ;
Kaufman, S ;
Sarosi, I ;
Shalhoub, V ;
Senaldi, G ;
Guo, J ;
Delaney, J ;
Boyle, WJ .
CELL, 1998, 93 (02) :165-176
[9]  
MORALESPIGA AA, 1995, J BONE MINER RES, V10, P663
[10]   Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor [J].
Morinaga, T ;
Nakagawa, N ;
Yasuda, H ;
Tsuda, E ;
Higashio, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 254 (03) :685-691